These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20476705)

  • 21. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.
    Prescrire Int; 2009 Feb; 18(99):11. PubMed ID: 19385126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making a case for a $2700-a-month drug.
    Sibbald B
    CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
    [No Abstract]   [Full Text] [Related]  

  • 23. Exploring the future of non-small cell lung cancer treatment.
    Ramalingam S
    Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
    [No Abstract]   [Full Text] [Related]  

  • 24. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hype over herceptin.
    Fitzpatrick J
    Nurs N Z; 2009 Mar; 15(2):4-5. PubMed ID: 19554708
    [No Abstract]   [Full Text] [Related]  

  • 27. Nanotechnology takes a new look at old drugs.
    Patlak M
    J Natl Cancer Inst; 2010 Dec; 102(23):1753-5. PubMed ID: 21088275
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant therapy in the elderly: making the right decision.
    Muss HB; Biganzoli L; Sargent DJ; Aapro M
    J Clin Oncol; 2007 May; 25(14):1870-5. PubMed ID: 17488985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 30. [Oncology 2010].
    Wörmann B
    Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1339-40. PubMed ID: 20556695
    [No Abstract]   [Full Text] [Related]  

  • 31. Update in oncology.
    Brahmer JR
    Ann Intern Med; 2005 Oct; 143(8):587-92. PubMed ID: 16230725
    [No Abstract]   [Full Text] [Related]  

  • 32. Maintenance therapy in advanced non-small cell lung cancer: a prime-time for change?
    Chan OS; Yeung RM; Lee AW
    Chin Med J (Engl); 2013 Jun; 126(12):2390-8. PubMed ID: 23786960
    [No Abstract]   [Full Text] [Related]  

  • 33. Trust's refusal to fund trastuzumab was "arbitrary".
    Dyer C
    BMJ; 2006 Apr; 332(7544):747. PubMed ID: 16575068
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Nixon NA; Khan OF; Imam H; Tang PA; Monzon J; Li H; Sun G; Ezeife D; Parimi S; Dowden S; Tam VC
    Cancer; 2017 Dec; 123(23):4672-4679. PubMed ID: 28817175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What patients and providers should understand about economic evaluations in oncology.
    de Souza JA; de Lima Lopes G
    J Oncol Pract; 2012 Jul; 8(4):231-2. PubMed ID: 23180987
    [No Abstract]   [Full Text] [Related]  

  • 36. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Vectibix (panitumumab)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):175-6. PubMed ID: 19581184
    [No Abstract]   [Full Text] [Related]  

  • 37. New Math on Drug Cost-Effectiveness.
    Bach PB
    N Engl J Med; 2015 Nov; 373(19):1797-9. PubMed ID: 26535510
    [No Abstract]   [Full Text] [Related]  

  • 38. Optional copayments on anti-cancer drugs.
    van de Vooren K; Curto A; Garattini L
    BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
    [No Abstract]   [Full Text] [Related]  

  • 39. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 40. Colorectal cancer drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2017 Aug; 16(8):525-526. PubMed ID: 28529321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.